Research programme: CD40-targeted therapeutics - Phylogica

Drug Profile

Research programme: CD40-targeted therapeutics - Phylogica

Latest Information Update: 28 Feb 2011

Price : $50

At a glance

  • Originator Phylogica
  • Class Peptides
  • Mechanism of Action CD40 ligand modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 24 Feb 2011 The programme is in active development
  • 08 Feb 2010 Preclinical trials in Rheumatoid arthritis in Australia (Parenteral)
  • 08 Feb 2010 Preclinical trials in Inflammatory bowel disease in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top